WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their option to p ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Adamas Trust, Inc. (Nasdaq: ADAM) (the “Company” or “Adamas”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.23 per share on shares of its common stock for the quarter ending December 31, 2025. The dividend will be payable on January 28, 2026 to common stockholders of record as of the close of business on December 22, 2025. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fi ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0 ...

JOHANNESBURG, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ: LSAK, JSE: LSK) ("Lesaka") today announced it will release second quarter 2026 results after the U.S. market close on February 4, 2026. Lesaka management will host a presentation webcast and conference call on February 5, 2026, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: https://www.corpcam.com/Lesaka05022026 P ...

ARR increased 34% year-over-year to $754 millionQ3 revenue increased 33% year-over-year to $184.2 millionSurpassed $1 billion in Remaining Performance Obligations, reflecting 41% year-over-year growthQ3 net cash provided by operating activities was $11.2 million, representing 6% of revenueQ3 free cash flow was $10.6 million, representing a positive 6% free cash flow margin SANTA CLARA, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Netskope (NASDAQ:NTSK) a leader in modern security and networking for the cloud a ...

PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ: DVLT) (“Datavault AI” or the “Company”), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the “Datavault Board”) has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the “Meme Coin”) to all eligible record equityholders of Datavault AI. Dec. 24, 2025, will also be the distribution date for Datavault AI’s volunt ...

Core Insights - Crinetics Pharmaceuticals has initiated the CALM-CAH Phase 3 trial for atumelnant, a novel oral ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) [1][2] - The trial will assess atumelnant's effectiveness in normalizing adrenal androgen levels and reducing glucocorticoid levels to physiological ranges, setting a new standard for disease control assessment [2][3] - Atumelnant is the first small molecule ACTH receptor antagonist in late-stage clinical development, showing promising results in a Phase 2 study with significant reductions in key biomarkers [2][4] Company Overview - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and innovative therapies [5] - The company has a robust pipeline, including its lead product PALSONIFY™ for acromegaly and atumelnant for CAH and ACTH-dependent Cushing's syndrome [6][7] - Crinetics has received Orphan Drug Designation from the FDA for atumelnant, highlighting its potential impact on rare diseases [3]

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The ...

MITCHEL FIELD, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the second quarter and fiscal year 2026. Revenue for the three and six months ended October 31, 2025, was approximately $17.1 million and $30.9 million, respectively, compared to $15.8 million and $30.9 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and six months ended October 31, 2 ...

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cartier Silver Corporation (CSE:CFE) (“Cartier Silver” or the “Company”) announces the grant of stock options to directors, officers and consultants to purchase an aggregate of 3,430,000 common shares of the Company, exercisable at $0.24 per share at any time on or before December 11, 2030. The grants are subject to the terms of Cartier Silver’s stock option plan. In accordance with regulatory requirements, any shares issued pursuant to the exercise of such options ...